<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586088</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-CMY-2020-2103</org_study_id>
    <nct_id>NCT04586088</nct_id>
  </id_info>
  <brief_title>Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure</brief_title>
  <official_title>Apatinib Combined With Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma Who Failed at Least the First-line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib&#xD;
      and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the&#xD;
      first-line treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2020</start_date>
  <completion_date type="Anticipated">May 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the proportion of patients whose tumors shrink to complete response (CR) or partial response (PR) and remain for a certain period of time according to RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who achieved disease control</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the proportion of subjects who achieve CR+PR+stable disease (SD) for at least 4 weeks according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who achieved clinical benefit</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as maintaining the efficacy of CR+PR+SD for at least 6 months according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the period from the start of enrollment until disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the time from the first assessment of CR and PR to the first assessment of PD or death caused by any cause according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>NCI-CTC5.0 standard was adopted, and the safety was assessed mainly by clinical laboratory tests, ECOG-PS score, physical examination, electrocardiogram, and adverse event results.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Recurrent Nasopharyngeal Carcinoma</condition>
  <condition>Metastatic Nasopharyngeal Carcinoma</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Immunotherapy</condition>
  <condition>Molecular Targeted Therapy</condition>
  <arm_group>
    <arm_group_label>Apatinib plus Camrelizumab arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive apatinib plus camrelizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib plus Camrelizumab</intervention_name>
    <description>Subjects receive Apatinib, 250mg, QD and Camrelizumab, 200mg, D1, Q3W. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.</description>
    <arm_group_label>Apatinib plus Camrelizumab arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female; 18-70 years of age.&#xD;
&#xD;
          2. Subjects diagnosed with pathological confirmed metastatic nasopharyngeal carcinoma, or&#xD;
             subjects with recurrent NPC that is unfit for local treatment&#xD;
&#xD;
          3. Underwent at least first-line treatment failure&#xD;
&#xD;
          4. ECOG performance status of 0 or 1.&#xD;
&#xD;
          5. Life expectancy more than 12 weeks.&#xD;
&#xD;
          6. Subjects enrolled must have measurable lesion(s) according to response evaluation&#xD;
             criteria in solid (RECIST) v1.1.&#xD;
&#xD;
          7. Adequate organ function assessed by laboratory parameters during the screening period.&#xD;
&#xD;
          8. Female subjects agree not to be pregnant or lactating from beginning of the study&#xD;
             screening through at least 3 months after receiving the last dose of study treatment.&#xD;
             Both men and women of reproductive potential must be willing and able to employ a&#xD;
             highly effective method of birth control/contraception to prevent pregnancy.&#xD;
&#xD;
          9. Able to understand and sign an informed consent form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with any active autoimmune disease or history of autoimmune disease, or&#xD;
             history of syndrome that requires systemic steroids or immunosuppressive medications,&#xD;
             including but not limited to the following: rheumatoid arthritis, pneumonitis, colitis&#xD;
             (inflammatory bowel disease), hepatitis, hypophysitis, nephritis, hyperthyroidism, and&#xD;
             hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy.&#xD;
             Subjects with the following conditions will not be excluded from this study: asthma&#xD;
             that requires intermittent use of bronchodilators, hypothyroidism stable on hormone&#xD;
             replacement, vitiligo, Graves' disease, or Hashimoto's disease. Additional exceptions&#xD;
             may be made with medical monitor approval;&#xD;
&#xD;
          2. Known history of hypersensitivity to any components of the Camrelizumab formulation or&#xD;
             other monoclonal antibodies ;&#xD;
&#xD;
          3. Concurrent medical condition requiring the use of immunosuppressive medications, or&#xD;
             immunosuppressive doses of systemic or absorbable topical corticosteroids. Doses 10&#xD;
             mg/day prednisone or equivalent are prohibited within 4 weeks before study drug&#xD;
             administration. Note: corticosteroids used for the purpose of IV contrast allergy&#xD;
             prophylaxis are allowed;&#xD;
&#xD;
          4. Subjects who underwent anti-PD-1 /PD-L antibody or anti-CTLA-4 antibody (or any other&#xD;
             antibody acting on T cell synergistic stimulation or checkpoint pathway) and&#xD;
             anti-angiogenic drugs.&#xD;
&#xD;
          5. Abnormal coagulation function (INR&gt;1.5×ULN, APTT&gt;1.5×ULN) with bleeding tendency.&#xD;
&#xD;
          6. The laboratory test values within 7 days before enrollment do not meet the relevant&#xD;
             standards.&#xD;
&#xD;
          7. Active central nervous system (CNS) metastases (indicated by clinical symptoms,&#xD;
             cerebral edema, steroid requirement, or progressive disease);&#xD;
&#xD;
          8. Diagnosed with other malignant tumors.&#xD;
&#xD;
          9. Uncontrolled clinically significant medical condition, including but not limited to&#xD;
             the following:&#xD;
&#xD;
               1. Hypertension that cannot be reduced to the normal range after antihypertensive&#xD;
                  drug&#xD;
&#xD;
               2. congestive heart failure (New York Health Authority Class &amp;gt; 2),&#xD;
&#xD;
               3. unstable angina,&#xD;
&#xD;
               4. myocardial infarction within the past 12 months,&#xD;
&#xD;
               5. clinically significant supraventricular arrhythmia or ventricular arrhythmia&#xD;
                  requiring treatment or intervention;&#xD;
&#xD;
         10. Active bleeding, ulcer, intestinal perforation, major surgery in the previous month;&#xD;
             Patients with tumors close to the internal carotid artery or other large vessels, thus&#xD;
             at risk of massive bleeding&#xD;
&#xD;
         11. Active infection or an unexplained fever; 38.5°C during screening visits or on the&#xD;
             first scheduled day of dosing (at the discretion of the investigator, subjects with&#xD;
             tumor fever may be enrolled);&#xD;
&#xD;
         12. History of immunodeficiency including seropositivity for human immunodeficiency virus&#xD;
             (HIV), or other acquired or congenital immune-deficient disease; active tuberculosis&#xD;
             (TB), anti-TB treatment is ongoing or within 1 year prior to screening; Evidence of&#xD;
             hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of reactivation&#xD;
             based on institutional guidelines and tests. Testing may include the following: HBV&#xD;
             DNA, HCV RNA, hepatitis B surface antigen, or anti-Hepatitis B core antibody.&#xD;
&#xD;
         13. Received any anti-infective vaccine (e.g. influenza vaccine, varicella vaccine, etc.)&#xD;
             within 4 weeks prior to enrollment.&#xD;
&#xD;
         14. Any other medical (eg, pulmonary, metabolic, congenital, endocrinal, or CNS disease),&#xD;
             psychiatric, or social condition deemed by the investigator to be likely to interfere&#xD;
             with a subject's rights, safety, welfare, or ability to sign informed consent,&#xD;
             cooperate, and participate in the study or would interfere with the interpretation of&#xD;
             the results;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming-Yuan Chen, MD, PhD</last_name>
    <phone>86-20-8734-3361</phone>
    <email>chmingy@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Yuan Chen, MD, PhD</last_name>
      <phone>86-20-8734-3361</phone>
      <email>chmingy@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ming-Yuan Chen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ming-Yuan Chen</investigator_full_name>
    <investigator_title>Chief physician, Proffessor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

